CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

204300Orig1s000

SUMMARY REVIEW
## Summary Review for Regulatory Action

<table>
<thead>
<tr>
<th>Date</th>
<th>June 27, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>From</td>
<td>Rigoberto Roca, M.D.</td>
</tr>
<tr>
<td>Subject</td>
<td>Deputy Division Director Summary Review</td>
</tr>
<tr>
<td>NDA/Supplement No.</td>
<td>204300/S-000</td>
</tr>
<tr>
<td>Applicant Name</td>
<td>Éclat Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Date of Original Submission</td>
<td>February 8, 2013/ Resubmitted after RTF: June 28, 2013 Complete Response letter issued April 28, 2014</td>
</tr>
<tr>
<td>Date of Complete Response Submission</td>
<td>June 6, 2014</td>
</tr>
<tr>
<td>PDUFA Goal Date</td>
<td>August 6, 2014</td>
</tr>
<tr>
<td>Proprietary Name / Established (USAN) Name</td>
<td>Vazculep / (phenylephrine hydrochloride ) injection</td>
</tr>
<tr>
<td>Dosage Forms / Strength</td>
<td>Solution for injection / 10 mg/mL</td>
</tr>
<tr>
<td>Proposed Indication</td>
<td>Treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.</td>
</tr>
<tr>
<td>Action</td>
<td>Approval</td>
</tr>
</tbody>
</table>

### Material Reviewed/Consulted

<table>
<thead>
<tr>
<th>OND Action Package, including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Officer Review</td>
</tr>
<tr>
<td>CDTL Review</td>
</tr>
<tr>
<td>Statistical Review</td>
</tr>
<tr>
<td>Pharmacology Toxicology Review</td>
</tr>
<tr>
<td>ONDQA Review</td>
</tr>
<tr>
<td>ONDQA Microbiology Review</td>
</tr>
<tr>
<td>Clinical Pharmacology Review</td>
</tr>
<tr>
<td>Project Management Staff</td>
</tr>
<tr>
<td>Pediatric and Maternal Health Staff</td>
</tr>
<tr>
<td>SEALD</td>
</tr>
<tr>
<td>OMP/OPDP</td>
</tr>
<tr>
<td>OMPQ/DGMPA/NDMAB</td>
</tr>
<tr>
<td>OSE/DMEPA</td>
</tr>
<tr>
<td>OSE/DPV II</td>
</tr>
<tr>
<td>DBRUP</td>
</tr>
</tbody>
</table>

CDTL = Cross-Discipline Team Leader  
DBRUP = Division of Bone, Reproductive, and Urologic Products  
DGMPA = Division of Good Manufacturing Practice Assessment  
DMEPA = Division of Medication Error Prevention and Analysis  
DPV = Division of Pharmacovigilance  
DRISK = Division of Risk Management  
NDMAB = New Drug Manufacturing Assessment Branch  
OMP = Office of Medical Policy  
OMPQ = Office of Manufacturing and Product Quality  
OND = Office of New Drugs  
ONDQA = Office of New Drug Quality Assessment  
OPDP = Office of Professional Drug Promotion  
OSE = Office of Surveillance and Epidemiology  
OSI = Office of Scientific  
SEALD = Study Endpoints and Labeling Development
1. Introduction
Éclat Pharmaceuticals, Inc., has submitted a 505(b)(2) new drug application (NDA) for phenylephrine hydrochloride. It is formulated as a 1% solution (10 mg/mL), and is intended to be administered through the intravenous route. The proposed indications are for treatment of hypotension during anesthesia, either as a bolus or as a continuous infusion.

The FDA recently approved another phenylephrine formulation for intravenous administration for similar indications (NDA 203826, WestWard Pharmaceuticals). The company has opted to only reference published literature in support for this application, and has opted not to reference any approved NDA for phenylephrine. Subsequently, the review of this application has relied only the information submitted by the applicant in the context of this application and has not relied on the FDA’s findings regarding NDA 203826.

The current submission constitutes a response to the Complete Response action letter that was issued to the Applicant on April 28, 2014. For an overview of the regulatory and scientific facts of this application and issues that were identified during the first review cycle, please refer to my memorandum dated April 28, 2014.

2. Background
Phenylephrine is a synthetic form derived from epinephrine and has been used clinically for more than 50 years. It is an α1-adrenergic receptor agonist, with little or no activity on α-2 receptors or β-receptors. The primary site of action is the vascular smooth muscle cells, resulting vascular smooth muscle contraction and subsequent increases in the systolic and diastolic blood pressures. Phenylephrine has also been noted to cause a reflex bradycardia and a decrease in the cardiac output, presumably due to the increased afterload. Phenylephrine has also been demonstrated to have an effect on renal, pulmonary, and splanchnic arteries, but minimal to no effect on cerebral vessels.

Regulatory History
The regulatory history is well summarized in Dr. Jiang’s and Dr. Breder’s reviews completed during the first review cycle. As noted in my memo from April 28, 2014, the Applicant originally submitted the application on February 8, 2013; however, the application was not filed due to the absences of an Integrated Summary of Efficacy and Integrated Summary of Safety. The Applicant addressed the deficiencies and resubmitted the application on June 28, 2013. A Complete Response letter was issued on April 28, 2014, due to the recommendation of “withhold” having been entered into the EES for a manufacturing site in [redacted] after an inspection.

3. Chemistry, Manufacturing, and Controls (CMC)
As noted in my memorandum from April 28, 2014, the review team found that the Applicant had submitted adequate information about the drug substance and drug product to support approval of the application. The results from the site inspection precluded approval during the first review cycle.
Since the time of the first action, the issues identified during the inspection have been adequately addressed, and the overall recommendation of “Acceptable” was entered into the EES on June 6, 2014. As noted in Drs. Nashed and Pinto review of June 17, 2014, the recommendation was for approval of the application, with the same post-marketing commitments and agreements that had been reached with the Applicant during the first review cycle.

**Outstanding or Unresolved Issues**

I concur with Drs. Nashed and Pinto that, with the resolution of the issues identified during the manufacturing site inspection, there are no product quality issues that would preclude approval of this application.

4. **Nonclinical Pharmacology/Toxicology**

The Applicant was not required to submit any additional nonclinical pharmacology/toxicology data to support this application.

**Outstanding or Unresolved Issues**

I concur with Drs. Nashed and Pinto that, with the resolution of the issues identified during the manufacturing site inspection, there are no product quality issues that would preclude approval of this application.

5. **Nonclinical Pharmacology/Toxicology**

The Applicant was not required to submit any additional nonclinical pharmacology/toxicology data to support this application.

**Outstanding or Unresolved Issues**

I concur with Drs. Nashed and Pinto that, with the resolution of the issues identified during the manufacturing site inspection, there are no product quality issues that would preclude approval of this application.

6. **Clinical Pharmacology/Biopharmaceutics**

The Applicant was not required to submit any additional data regarding the clinical pharmacology of phenylephrine.

**Outstanding or Unresolved Issues**

I concur with the conclusions reached by Drs. Delatte and Mellon indicated during the first review cycle that there were no pharmacology/toxicology issues that would preclude approval of this supplement. In a memo dated June 18, 2014, Dr. Delatte and Dr. Mellon reiterated their recommendation for approval and for the completion by the Applicant the Post-marketing Requirements (PMRs) identified during the first review cycle, which are as follows:

1. A fertility and early embryonic development toxicology study in the rat model for phenylephrine hydrochloride.
2. An embryo-fetal developmental toxicology study using the rat model for phenylephrine hydrochloride.
3. An embryo-fetal developmental toxicology study using the rabbit model for phenylephrine hydrochloride.
4. A peri- and post-natal developmental toxicology study in the rat model for phenylephrine hydrochloride.

I concur with the conclusions reached by Drs. Delatte and Mellon.

7. **Clinical Microbiology**

Vazculep is not a therapeutic antimicrobial; therefore, clinical microbiology data were not required or submitted for this application.
8. Clinical/Statistical – Efficacy
The Applicant was not required to submit any additional data to support the efficacy of phenylephrine for the requested indication.

*Outstanding or Unresolved Issues*
I concur with the overall conclusion reached by the review team that the data submitted by the Applicant are adequate to support the indication of treatment of hypotension.

9. Safety
As noted by Dr. Breder in is memo, the Applicant updated the safety database in support of this application by reviewing the medical literature published between October 11, 2013 and June 3, 2014. The Applicant’s search was limited to articles in English-language publications that were related to humans, and containing the keyword “phenylephrine.” The Applicant’s search yielded approximately 40 articles, 8 of which were deemed to be relevant to this NDA. The Applicant’s conclusion was that no new adverse events, unexpected severity of known adverse events, or unexpected serious or clinically significant important safety findings were identified.

Dr. Breder agreed with the Applicant’s conclusions.

*Outstanding or Unresolved Issues*
I concur with the review team that the safety profile of phenylephrine has been adequately characterized by the extensive history of clinical use, the published literature, and evaluation of the FDA’s Adverse Event Report System.

10. Advisory Committee Meeting
An advisory committee meeting was not convened for this application during the first review cycle, as there were no issues in this application that required presentation or discussion at an advisory committee meeting. That assessment remained unchanged.

10. Pediatrics
The Applicant requested a waiver of the studies required under the Pediatric Research Equity Act of 2007 (PREA) [8][4]. The Division concurred with the Applicant with respect to patients less than 12 years of age, but considered the studies for patients older than 12 years as possible and desirable, in that dosing information in this age group would be relevant and useful to obtain.

At the Pediatric Review Committee (PeRC) meeting of March 5, 2014, the committee reviewed the Applicant’s proposal and the division’s position, and concurred with the division that the study in the older age group would be useful. It was also decided that this study could be deferred.
These conclusions were conveyed to the Applicant and a timeline for the submission of the final report submission was agreed upon.

11. Other Relevant Regulatory Issues
There were no new regulatory issues identified during this review cycle.

Outstanding or Unresolved Issues
There are no other unresolved relevant regulatory issues.

12. Labeling
The labeling was discussed with the Applicant during the first review cycle, and agreements were reached on the text of the document.

13. Decision/Action/Risk Benefit Assessment
   Regulatory Action
   Approval

Risk:Benefit Assessment
I concur with the review team that the Applicant has submitted substantial evidence to support the effectiveness and safety of phenylephrine for the treatment of hypotension that is primarily associated with vasodilation. As noted in my memorandum of April 28, 2014, even though phenylephrine has been associated with the risk of hypertension and reflex bradycardia, an episode of perioperative hypotension is associated with increased morbidity and mortality, whereupon the use of phenylephrine in this clinical situation results in a favorable risk:benefit assessment.

Recommendation for Postmarketing Risk Management Activities
None.

Recommendation for other Postmarketing Study Requirements
These requirements have been discussed with the Applicant during the course of the first review cycle of the application.

   a) Clinical (as part of the PREA requirements)
      A clinical study in patients between the ages of 12 and 16 years of age, to evaluate the pharmacokinetics, efficacy, and safety of different doses of phenylephrine hydrochloride injection in patients undergoing general anesthesia and/or neuroaxial anesthesia.
b) Non-clinical
   1. A fertility and early embryonic development toxicology study in the rat model for phenylephrine hydrochloride.
   2. An embryo-fetal developmental toxicology study using the rat model for phenylephrine hydrochloride.
   3. An embryo-fetal developmental toxicology study using the rabbit model for phenylephrine hydrochloride.
   4. A peri- and post-natal developmental toxicology study in the rat model for phenylephrine hydrochloride.

Recommendation for other Postmarketing Study Commitments

These Postmarketing Commitments (PMCs) were discussed with the Applicant during the course of the first review cycle of the application. Agreements noted in the CMC reviews as having been reached during the first review cycle are also listed here as PMCs.

1. Submission of data and shelf-life acceptance criteria for the content of sodium metabisulfite in drug product.

2. Submission of data and data-based release acceptance criteria for the content of sodium metabisulfite in drug product.

3. Submission of annual stability reports with evaluation of instability trends upon analysis of data collected for commercial scale validation batches.

4. Submission of an evaluation of trends in sodium metabisulfite content in the context of changes in pH and impurity levels as well as analyze the impact of storage orientation on instability trends.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RIGOBERTO A ROCA
06/27/2014
## Summary Review for Regulatory Action

<table>
<thead>
<tr>
<th>Date</th>
<th>April 28, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>From</td>
<td>Rigoberto Roca, M.D.</td>
</tr>
<tr>
<td>Subject</td>
<td>Deputy Division Director Summary Review</td>
</tr>
<tr>
<td>NDA/Supplement No.</td>
<td>204300/S-000</td>
</tr>
<tr>
<td>Applicant Name</td>
<td>Éclat Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Date of Submission</td>
<td>February 8, 2013 / Resubmitted after RTF: June 28, 2013</td>
</tr>
<tr>
<td>PDUFA Goal Date</td>
<td>April 28, 2014</td>
</tr>
<tr>
<td>Proprietary Name / Established (USAN) Name</td>
<td>Vazculep / (phenylephrine hydrochloride) injection</td>
</tr>
<tr>
<td>Dosage Forms / Strength</td>
<td>Solution for injection / 10 mg/mL</td>
</tr>
<tr>
<td>Proposed Indications</td>
<td>1. Treatment of hypotension during anesthesia</td>
</tr>
<tr>
<td>Action</td>
<td>1. Treatment of hypotension during anesthesia: Complete Response</td>
</tr>
</tbody>
</table>

### Material Reviewed/Consulted

<table>
<thead>
<tr>
<th>OND Action Package, including:</th>
<th>Timothy Jiang, MD, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Officer Review</td>
<td>Christopher Breder, MD, PhD</td>
</tr>
<tr>
<td>CDTL</td>
<td>Janice Derr, PhD / Thomas Permutt, PhD</td>
</tr>
<tr>
<td>Statistical Review</td>
<td>Marcus Delatte, PhD / R. Daniel Mello, PhD</td>
</tr>
<tr>
<td>Pharmacology Toxicology Review</td>
<td>Eugenia Nashed, PhD / Prasad Peri, PhD</td>
</tr>
<tr>
<td>ONDQA Review</td>
<td>Stephen Langille, PhD / John Metcalfe, PhD</td>
</tr>
<tr>
<td>ONDQA Microbiology Review</td>
<td>David Lee, PhD / Yun Xu, PhD</td>
</tr>
<tr>
<td>Clinical Pharmacology Review</td>
<td>Kimberly Compton, RPh / Matthew Sullivan / Parinda Jani</td>
</tr>
<tr>
<td>Project Management Staff</td>
<td>Jeanine Best, MSN, RN / Miriam Dinatale, MD / Amy Taylor, MD / Lyme Yao, MD</td>
</tr>
<tr>
<td>Pediatric and Maternal Health Staff</td>
<td>Jeanne Delasko / Eric Brodsky, MD</td>
</tr>
<tr>
<td>SEALD</td>
<td>Eunice Chung-Davies, PharmD</td>
</tr>
<tr>
<td>OMP/OPDP</td>
<td>Juandria Williams / Mahesh Ramanadham, PharmD</td>
</tr>
<tr>
<td>OMPQ/DGMPA/NDMAB</td>
<td>Aleksander Winiarski, PharmD / Julie Neshiewat, PharmD</td>
</tr>
<tr>
<td>OSE/DMEPA</td>
<td>Tara Argual, PharmD / Jane Gilbert, MD / Sara Camilli, PharmD / Allen Brinker, MD / Scott Proestel, MD</td>
</tr>
<tr>
<td>OSE/DPV II</td>
<td>Barbara Wesley, MD / Christina Chang, MD / Audrey Gassman, MD</td>
</tr>
</tbody>
</table>

**Legend:**
- CDTL = Cross-Discipline Team Leader
- DMEPA = Division of Medication Error Prevention and Analysis
- DPV = Division of Pharmacovigilance
- DRISK = Division of Risk Management
- DMBG = New Drug Manufacturing Assessment Branch
- OMP = Office of Medical Policy
- OMPQ = Office of Manufacturing and Product Quality
- OND = Office of New Drugs
- ONDQA = Office of New Drug Quality Assessment
- OPDP = Office of Professional Drug Promotion
- OSE = Office of Surveillance and Epidemiology
- OSI = Office of Scientific
- SEALD = Study Endpoints and Labeling Development
1. Introduction

Éclat Pharmaceuticals, Inc., has submitted a 505(b)(2) new drug application (NDA) for phenylephrine hydrochloride. It is formulated as a 1% solution (10 mg/mL), and is intended to be administered through the intravenous route. The proposed indications are for treatment of hypotension during anesthesia, either as a bolus or as a continuous infusion.

The FDA recently approved another phenylephrine formulation for intravenous administration for similar indications (NDA 203826, Westward Pharmaceuticals). The company has opted to only reference published literature in support for this application, and has opted not to reference any approved NDA for phenylephrine. Subsequently, the review of this application has relied only the information submitted by the applicant in the context of this application and has not relied on the FDA’s findings regarding NDA 203826.

This review will provide an overview of the regulatory and scientific facts of this application and issues that were identified during the course of the review of the submission. Aspects that will be touched upon include the regulatory history, the adequacy of the data to support the application, and the labeling requested by the Applicant.

2. Background

Phenylephrine is a synthetic form derived from epinephrine and has been used clinically for more than 50 years. It is an α1-adrenergic receptor agonist, with little or no activity on α-2 receptors or β-receptors. The primary site of action is the vascular smooth muscle cells, resulting in vascular smooth muscle contraction and subsequent increases in the systolic and diastolic blood pressures. Phenylephrine has also been noted to cause a reflex bradycardia and a decrease in the cardiac output, presumably due to the increased afterload. Phenylephrine has also been demonstrated to have an effect on renal, pulmonary, and splanchnic arteries, but minimal to no effect on cerebral vessels.

Regulatory History

The Applicant originally submitted the application on February 8, 2013; however, the application was not filed due to the absences of an Integrated Summary of Efficacy and Integrated Summary of Safety. A meeting was held with the Applicant on June 13, 2013, at which the appropriate format for the submission was discussed.
3. Chemistry, Manufacturing, and Controls (CMC)

General Product Considerations

Drug Substance
Phenylephrine chloride is a ___________, soluble in aqueous media. The Applicant purchases the drug substance from ___________, and it is manufactured under DMF # ___________. The DMF was reviewed and deemed to be adequate.

The manufacturing site is in ___________, and previous inspection resulted in several GMP issues that needed to be addressed. A re-inspection of the facility was conducted by the Agency on ___________.

Drug Product
The drug product is a sterile, non-pyrogenic solution. ___________. Inspection of the manufacturing facility and two contractor sites were deemed acceptable.

As noted in Dr. Nashed’s review, the drug product is packaged in Type 1 clear glass vials with ___________ stoppers and ___________. The Applicant proposes three fill volumes for marketing: 1 mL, 5 mL, and 10 mL, with the latter two intended only for pharmacy distribution. Data were submitted to support storage at controlled room temperature, 25 °C (77°F), with excursions permitted from 15° to 30° C (59° to 86°F). The stability data submitted supports an ___________ expiry data, however, the Applicant’s agreement to monitor the observed instability trends and to provide the evaluation report in the annual report has permitted the review team to grant a 24-month expiry period.

Facilities Reviews/Inspections
The drug product manufacturing site ___________ and two testing sites were inspected and deemed acceptable. The drug substance manufacturing site in ___________ had previously been inspected and several issues had been identified that needed to be corrected. That site was re-inspected on ___________. An overall recommendation is pending at this time in the Establishment Evaluation System (EES), however, a recommendation of “withhold” was entered into the EES for the site in ___________. Regarding the implications on this entry in EES for the action on this application, Dr. Mahesh Ramanadham, the Acting Branch Chief in the New Drug Manufacturing Assessment Branch (NDMAB) responded in an email on April 25, 2014, as follows:

Regarding action; if we remain in the same situation (i.e. no report), we should still be able to take action as the international team entered their recommendation in EES. In my experience we don’t usually miss action when we are waiting for additional information for the site compliance evaluation (as site evaluations are not tied to GRMP dates). We usually take action on the most current information we have available, unless there is a compelling reason to miss the date (ex unapproved new drug initiative, current shortage, etc…). As the recommendations are in EES, we have what we need in order to take action, but that decision is ultimately up to DAAP.
Product Quality Microbiology

The evaluation of the process and process controls, and their validation, was conducted by Dr. Stephen Langille. His conclusions were that the information provided in the submission was adequate to support approval.

Specific Issues Identified in the Course of the Review

The following issues were identified in the course of the review and resolved (reproduced from Dr. Nashed’s review:

- Data documenting the absence of a substance to be submitted by April 2, 2014, per agreement provided on March 19, 2014.

  The Applicant discussed preliminary results for the content of potential leachable in communication dated March 19, 2014. Applicant agreed to provide final test results and brief method validation in NDA amendment by April 2, 2014. The preliminary negative results for the potential leachable and the provided agreement alleviate the CMC safety concerns regarding this leachable. At this point we do not consider it necessary to include the testing for leachables in the drug product stability protocol.

- Specifications for the content of sodium metabisulfite during shelf-life of the product as described in PMC #1.

- Tightening of the tentative release specifications for the content of sodium metabisulfite as described in PMC #2.

  The proposed PMCs are considered sufficient to address the potential safety and quality aspects associated with the level of sodium metabisulfite in the drug product formulation. Although most likely there is a minimum level of the required to assure the strength of the drug product, the stability of the formulation is indirectly controlled by the acceptance criteria for pH, individual impurities and total impurities. In addition, a report will be provided to the Agency documenting the changes occurring in the level of sodium metabisulfite throughout the life-time of the drug product, along with a study documenting a minimum level of sodium metabisulfite required to sustain the function.

- Special stability report to be submitted in each Annual Report. It will include analysis of instability trends, including results for all stability-indicating attributes, including the requested data (storage orientation), as described in Agreement #1.

  The stability data submitted to this NDA include results for 9 registration batches for samples stored in one orientation for 18 months. Data do not include content of (see PMCs) and indicate different instability trends (pH, impurities) for small fill vials (1 mL and 5 mL) with large head volume in comparison to the 10 mL fill with small head volume, most likely due to the product fills after storage, however the results are within specification limits. Also, no report or data documenting the preferred-for-storage orientation for the product is currently available.

  The provided Agreement, to include additional storage orientation for stability samples and to provide analysis of the instability trends for the commercial products in each annual report, is adequate to monitor the quality of the proposed-for-marketing product and sufficiently addresses the CMC concerns.
It is noted that these issues are being addressed with post-marketing commitments and agreements, and do not impact the approvability of the application.

**Outstanding or Unresolved Issues**
As noted above, the email communication from NDMAB indicated that, since there is a recommendation in EES, we have what we need to in order to take an action on this application. Due to the withhold recommendation, this application cannot be approved until the issues identified in the inspection are resolved.

### 4. Nonclinical Pharmacology/Toxicology

**General Considerations**
The Applicant did not conduct any nonclinical pharmacology or toxicology studies. In previous interactions with the Applicant prior to the submission of the application, the Division had indicated that adequate clinical experience with the product could potentially obviate the need for general toxicology studies to support the application.

Dr. Delatte noted in his review that there are no novel excipients with the drug product formulation, and that all drug substance impurities and drug product degradants have been adequately qualified for safety. It was also noted that the container closure system has been adequately qualified for safety.

All the nonclinical information intended to support the application and inform the label with respect to genotoxicity, carcinogenicity, and reproductive and development toxicity, was derived from the published literature.

**Carcinogenicity**
The results of a 2-year study in rats and a 2-year study in mice that were treated with phenylephrine via their diet were available in the published literature, and it reported no evidence of carcinogenicity under the conditions of the study. The dose employed in the rat study (50 mg/kg or 300 mg/m²) is 48-fold the human dose and the dose used in the mice study (270 mg/kg or 810 mg/m²) is 131-fold the maximum daily dose human dose of 10 mg/60 kg person (0.17 mg/kg or 6.3 mg/m²), based on body surface area comparisons.

**Genotoxicity**
The published literature contained the results from phenylephrine studies conducted with the Ames assay, in vitro mouse lymphoma assay, in vitro assay for chromosomal aberrations, and the in vitro alkaline elution assay in rat hepatocytes. Dr. Delatte concludes that, based on overall weight-of-evidence all the genetic toxicology and carcinogenicity data, there was no concern for genotoxicity.

**Reproductive Toxicology**
Dr. Delatte noted in his review that reports of reproductive toxicology studies conducted in rabbits and sheep were available in the literature. The following is a quotation from his review regarding the results of these studies and their implications.

Review of the literature identified a few nonclinical studies that begin to characterize the potential impact of phenylephrine on reproductive and developmental endpoints.
Specifically, reproductive toxicology studies in normotensive rabbits were conducted to evaluate the effect of phenylephrine administration during various stages of gestation. These studies indicate that subcutaneous administration of phenylephrine to pregnant rabbits (0.33 mg/kg, TID) resulted in premature labor onset, decreased litter weights, increased neonate deaths and still births, and histopathology findings in the placenta such as necrosis, thickened vascular walls, and narrowed lumina. Studies in normotensive pregnant sheep demonstrated that phenylephrine increases blood pressure and produces reflex bradycardia in both the ewe and the fetus and decreases uterine blood flow at doses that were slightly greater than the upper dosing range in humans. These findings, in normotensive animals, suggest the potential for risk and should be included in the drug product labeling at this point. However, none of the studies are deemed adequate by current standards, and the results from studies in normotensive animals may not reflect clinical conditions if the drug is used only to treat hypotension and restore blood pressure to normal.

Based on the limited data in the literature, the full reproductive and developmental toxicology study battery of studies are recommended as PMRs. Careful design of these studies to include assessment of clinically relevant conditions, if possible, should be discussed with the Sponsor.

Other Nonclinical Evaluations of Interest
There were no other nonclinical evaluations of interest.

Outstanding or Unresolved Issues
I concur with the conclusions reached by Drs. Delatte and Mellon that there are no pharmacology/toxicology issues that would preclude approval of this supplement. I also concur with their recommendation that the Applicant conduct the following Post-marketing Requirements (PMRs):

1. A fertility and early embryonic development toxicology study in the rat model for phenylephrine hydrochloride.

2. An embryo-fetal developmental toxicology study using the rat model for phenylephrine hydrochloride.

3. An embryo-fetal developmental toxicology study using the rabbit model for phenylephrine hydrochloride.

4. A peri- and post-natal developmental toxicology study in the rat model for phenylephrine hydrochloride.

6. Clinical Pharmacology/Biopharmaceutics

General Considerations
The Applicant did not conduct any clinical pharmacology studies. All the information regarding the clinical pharmacology of their product was derived from published literature. Dr. Lee noted in his review that the Applicant’s submission included studies to address the pharmacokinetic, pharmacodynamic, and drug-drug interaction sections of the label.

Pharmacokinetic Information
Dr. Lee noted the following in his review (note: in his review, phenylephrine is abbreviated as “PE”):

Following an intravenous infusion (12.5 to 20 minutes) of 1 mg (mean dose of 0.84 ± 0.17 mg) tritiated phenylephrine (3H-PE), the PE concentration-time curve exhibited
biphasic decline, as observed by an initial rapid distribution followed by relatively slow elimination. The reported average steady state volume of distribution (Vss) and elimination half-life were 340 L (range 184 to 543 L) and 151 minutes (2.51 h based on β-phase), respectively. The observed distribution phase was rapid (less than 5 minutes based on α-phase).

Phenylephrine is metabolized primarily by monoamine oxidase and sulfotransferase. Based on 3H-PE intravenous administration, approximately 86% (approximately 80% of the administered dose was eliminated within first 12 h) of the intravenously administered dose was recovered in the urine within 48 h. The excreted unchanged drug (i.e., parent PE) was 16% of the dose in the urine at 48 h post intravenous administration. There are two major metabolites with approximately 57 and 8% of the administered dose excreted as m-hydroxymandelic acid and sulfate conjugates, respectively. The metabolites are considered not pharmacologically active.

**Pharmacodynamic Information**

Dr. Lee noted in his review that the literature indicates that phenylephrine’s onset of action is within seconds, and lasts minutes after administration, but is also dependent on the subject’s sensitivity. The two tables that follow are adapted from Dr. Lee’s review, summarize the findings from the literature, and the overall assessment is that the pressor responses were in the 6 to 30 mm Hg range when a bolus dose was given with or without a follow-up infusion.

**Blood pressure response to phenylephrine (PE) bolus intravenous injection (SBP: systolic blood pressure; SAP: systolic arterial pressure; MAP: mean arterial pressure)**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient population</th>
<th>PE Dose</th>
<th>Blood Pressure Just Prior to PE Application</th>
<th>Blood Pressure After PE Application</th>
<th>Δ BP</th>
<th>Time after PE Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goertz et al. 1993b</td>
<td>Coronary artery disease and valvular aortic stenosis</td>
<td>1 μg/kg (~72 μg³)</td>
<td>MAP 69-71 mm Hg</td>
<td>MAP 94-99 mm Hg</td>
<td>23-30 mm Hg</td>
<td>60 sec</td>
</tr>
<tr>
<td>Dyer et al. 2008b</td>
<td>Cesarean delivery with spinal anesthesia</td>
<td>50-100 μg, repeated every minute as needed</td>
<td>MAP 91 mm Hg</td>
<td>MAP 108 mm Hg</td>
<td>17 mm Hg</td>
<td>Within 24 to 40 seconds of dosing</td>
</tr>
<tr>
<td>Goertz et al. 1993a</td>
<td>Elective minor abdominal or orthopedic surgery</td>
<td>2 μg/kg (~148 μg³)</td>
<td>61 mm Hg</td>
<td>83 mm Hg</td>
<td>22 mm Hg</td>
<td>30 sec</td>
</tr>
<tr>
<td>Ishiyama et al. 2003</td>
<td>Elective surgery under combined general and epidural anesthesia</td>
<td>2 μg/kg (~112 μg³)</td>
<td>61 mm Hg</td>
<td>80 mm Hg</td>
<td>~19 mm Hg</td>
<td>2.5 min</td>
</tr>
<tr>
<td>Reference</td>
<td>Patient population</td>
<td>PE Dose</td>
<td>Blood Pressure Just Prior to PE Application</td>
<td>Blood Pressure After PE Application</td>
<td>Δ BP</td>
<td>Time after PE Dose</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------------------</td>
<td>---------</td>
<td>---------------------------------------------</td>
<td>-----------------------------------</td>
<td>------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Dyer et al. 2009</td>
<td>Cesarean delivery with spinal anesthesia</td>
<td>80 μg</td>
<td>72.8 mm Hg</td>
<td>98.5 mm Hg</td>
<td>25.7 mm Hg</td>
<td>61.8 sec</td>
</tr>
<tr>
<td>Alahuhta et al. 1992</td>
<td>Cesarean delivery with spinal anesthesia (followed by 100 μg bolus)</td>
<td>100 μg bolus</td>
<td>SAP 109 mm Hg (Hg)</td>
<td>SAP 115 mm Hg</td>
<td>6 mm Hg</td>
<td>-</td>
</tr>
</tbody>
</table>

a. μg/kg x mean weight 69-75 kg = 69-75 μg  
b. Blood pressure response was measured after multiple PE doses  
c. 2 μg/kg x mean patient weight of 74 kg = 148 μg  
d. 2 μg/kg x mean patient weight of 56 kg = 112 μg  
e. Based on mean MAP values pre and post-vasopressor

Blood pressure response to phenylephrine (PE) intravenous infusion with or without initial bolus injection (SBP: systolic blood pressure; SAP: systolic arterial pressure; MAP: mean arterial pressure)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient population</th>
<th>PE Dose</th>
<th>Baseline MAP</th>
<th>Post-dose MAP</th>
<th>MAP Response</th>
<th>Time of Post-dose Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nygren et al. 2006</td>
<td>Coronary artery bypass grafting surgery</td>
<td>0.50 ± 0.22 μg/kg/min (range, 0.21±0.94 μg/kg/min) ~35 μg/min</td>
<td>68 ± 5 mm Hg</td>
<td>92 ± 4 mm Hg</td>
<td>24 mm Hg</td>
<td>NA</td>
</tr>
<tr>
<td>Brooker et al. 1997</td>
<td>Elective surgery with tetracaine spinal</td>
<td>40 μg bolus (followed by infusion with 0.5 μg/kg/min) MAP 82 mm Hg</td>
<td>MAP 100 mm Hg</td>
<td>MAP 100 mm Hg</td>
<td>MAP 100 mm Hg</td>
<td>MAP 100 mm Hg</td>
</tr>
</tbody>
</table>

a. Calculated from mean weight of population studied in Brooker et al. (1997)

Dr. Lee also noted in his review that, although phenylephrine’s pressor activity is dependent on the concentration being infused, increasing the duration of infusion did not significantly increase the mean arterial pressure (the following table is adapted from Dr. Lee’s review).

### Pressor response to phenylephrine dose

<table>
<thead>
<tr>
<th>Phenylephrine dose</th>
<th>Duration of Infusion (min)</th>
<th>Baseline MAP* (mm Hg)</th>
<th>Post-dose MAP (mm Hg)</th>
<th>Δ in MAP (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.15 μg/kg/min (~10 μg/min)</td>
<td>4</td>
<td>83 ± 2</td>
<td>85 ± 2</td>
<td>2</td>
</tr>
<tr>
<td>0.30 μg/kg/min (~20 μg/min)</td>
<td>8</td>
<td>85 ± 2</td>
<td>85 ± 2</td>
<td>2</td>
</tr>
<tr>
<td>0.45 μg/kg/min (~30 μg/min)</td>
<td>8</td>
<td>89 ± 2</td>
<td>89 ± 2</td>
<td>6</td>
</tr>
</tbody>
</table>

*MAP = mean arterial blood pressure
**Special Populations**

The Applicant submitted literature to address special populations. With regard to age, sex, and race, Dr. Lee concluded that the data in the literature were either inconclusive or inadequate to result in dosing modification recommendations.

With respect to patients with hepatic impairment, the data indicated that the cardiovascular response, i.e., increases in blood pressure, was attenuated in patients with severe hepatic disease, potentially requiring higher doses. Dr. Lee proposed wording to include in the labeling to reflect this finding.

Dr. Lee also noted that, in patients with renal impairment, the data indicated that patients with end-stage renal disease exhibited an increased responsiveness to phenylephrine. Dr. Lee is proposing that the package insert note that patients with renal impairment may be started at a lower than recommended dose, with adjustments being made as necessary.

**Thorough QT Study**

Dr. Breder noted in his review that the literature and the review of post-marketing adverse event reports by Drs. Argual and Gilbert did not identify a signal. Given the extensive history of clinical use, the team concluded that further assessment was not necessary.

**Drug-drug Interactions**

Concomitant medications may affect the sensitivity of tissue α-adrenoreceptors, resulting in either an increase or a decrease vasopressor effect of phenylephrine. In addition, certain moieties may act as agonists, or antagonists of phenylephrine, requiring adjustments in the dosage. Examples of the drugs that fall into each category will be included in the package insert.

**Outstanding or Unresolved Issues**

I concur with the conclusions reached by Dr. Lee and Dr. Yun that there are no clinical pharmacology issues that would preclude approval of this application.

7. **Clinical Microbiology**

Vazculep is not a therapeutic antimicrobial; therefore, clinical microbiology data were not required or submitted for this application.

8. **Clinical/Statistical – Efficacy**

The Applicant had proposed the following indication for their application: for the “treatment of hypotension during anesthesia.” The clinical review team reviewed them as two separate indications, because the patient populations would be different, the dosage recommendations could potentially be different, the amount and type of published information supporting each was different, and the risk:benefit assessment for each was different.

**Treatment of Hypotension**

As noted by Drs. Breder and Jiang, the published literature has several examples of the use of phenylephrine to raise blood pressure in a variety of surgical settings, including coronary artery
bypass grafts, valvular heart surgery, and elective abdominal, orthopedic, urologic, and gynecologic procedures. They also noted that the literature also describes the international experience with using phenylephrine to treat anesthesia-induced hypotension (from the United Kingdom, Canada, European Union, Asia, South America, and Africa).

The clinical team evaluated the data from 15 publications describing the use of phenylephrine to treat hypotension. They evaluated the data based on the type of anesthesia (general vs. neuraxial), method of administration (bolus vs. infusion), and patient population (obstetrical vs. non-obstetrical).

In reviewing the data, the team noted that bolus doses of 150 µg or 200 µg do not result in significant incremental increases in blood pressure compared to the lower doses. This observation is summarized in the table below (adapted from Dr. Breder’s review).

<table>
<thead>
<tr>
<th>PE Dose (µg)</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
<th>50</th>
<th>60</th>
<th>70</th>
<th>80</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 (n = 24)</td>
<td>-0.5</td>
<td>2.6</td>
<td>9.7</td>
<td>11.6</td>
<td>10.9</td>
<td>8.8</td>
<td>7.0</td>
<td>7.9</td>
<td>8.0</td>
</tr>
<tr>
<td>± 0.5</td>
<td>± 1.0</td>
<td>± 1.8</td>
<td>± 2.1</td>
<td>± 1.9</td>
<td>± 2.0</td>
<td>± 2.2</td>
<td>± 2.0</td>
<td>± 1.9</td>
<td></td>
</tr>
<tr>
<td>100 (n = 17)</td>
<td>0.9</td>
<td>5.6</td>
<td>12.6</td>
<td>14.6</td>
<td>15.6</td>
<td>13.6</td>
<td>13.7</td>
<td>13.1</td>
<td>12.9</td>
</tr>
<tr>
<td>± 1.0</td>
<td>± 1.7</td>
<td>± 1.8</td>
<td>± 2.2</td>
<td>± 2.6</td>
<td>± 2.8</td>
<td>± 2.8</td>
<td>± 2.8</td>
<td>± 3.1</td>
<td></td>
</tr>
<tr>
<td>150 (n = 3)</td>
<td>-1.0</td>
<td>1.0</td>
<td>8.7</td>
<td>14.7</td>
<td>13.7</td>
<td>12.0</td>
<td>10.3</td>
<td>9.3</td>
<td>8.7</td>
</tr>
<tr>
<td>± 0.6</td>
<td>± 4.6</td>
<td>± 6.0</td>
<td>± 2.4</td>
<td>± 0.70</td>
<td>± 1.5</td>
<td>± 2.0</td>
<td>± 2.0</td>
<td>± 1.8</td>
<td></td>
</tr>
<tr>
<td>200 (n = 6)</td>
<td>0.7</td>
<td>3.7</td>
<td>9.5</td>
<td>16.0</td>
<td>18.0</td>
<td>13.8</td>
<td>13.3</td>
<td>13.6</td>
<td>14.8</td>
</tr>
<tr>
<td>± 1.6</td>
<td>± 3.3</td>
<td>± 2.8</td>
<td>± 1.9</td>
<td>± 1.5</td>
<td>± 2.2</td>
<td>± 2.6</td>
<td>± 2.4</td>
<td>± 2.4</td>
<td></td>
</tr>
</tbody>
</table>

This observation may be due to the increased vascular resistance seen with the 200 µg dose, which, as an increased afterload, can have the effect of decreasing cardiac output.

The team felt that a dosing recommendation of bolus administrations of 40 to 100 µg, to be repeated if needed after a few minutes, struck the balance between achieving a therapeutic effect and not causing an untoward systemic effect.

With respect to phenylephrine infusion rates reported in the literature, Dr. Breder’s review noted that infusion rates of 0.21 µg/kg/min to 0.94 µg/kg/min resulted in increases of as much as 50% from baseline. The studies emphasized the importance of initiating the infusion at a low rate, and titrating to the desired blood pressure.
Outstanding or Unresolved Issues

I concur with the overall conclusion reached by the review team that the data submitted by the Applicant are adequate to support the indication of treatment of hypotension.

9. Safety

As noted by Dr. Jiang and Dr. Breder in their reviews, the safety database submitted by the Applicant was entirely derived from the published literature. In the studies that were intended to
support the treatment indications, there were 502 patients exposed. It was acknowledged that the reporting of the adverse events was not consistent throughout the studies, but, nevertheless, there was enough information contained in the studies to characterize the overall safety profile.

Deaths
There were no deaths reported in the literature submitted to support the safety of the product.

Non-fatal Serious Adverse Events
As noted by Dr. Jiang, adverse events that could be considered potentially life-threatening were reported, included episodes of hypertension and cardiac arrhythmias. However, the articles did not contain enough information to determine whether these events met the criteria to be classified as a serious adverse event.

The review team identified two cases in the literature of hypertensive emergencies that were not cited by the Applicant. The first was a case of stress-induced cardiomyopathy in a woman undergoing an elective cesarean section who had been dosed with phenylephrine to prevent hypotension. The second was a case of coronary dissection in a woman who was treated with phenylephrine for an episode of hypotension during an elective cesarean section.

Early Discontinuations
An assessment of the typed of adverse events that resulted in early discontinuations is not relevant for this indication due to the acute and temporary use of phenylephrine, particularly in the surgical setting.

Common Adverse Events
The most commonly reported adverse events in the published literature were hypertension, bradycardia, nausea and vomiting.

In addition, the review team obtained a consultation was obtained from the Office of Surveillance and Epidemiology, Division of Pharmacovigilance II, to review the FDA’s Adverse Event Report System (FAERS), as well as the published literature to identify any new safety signals about phenylephrine that could inform the labeling. Their findings were summarized as follows:

The search of the FAERS database retrieved 137 reports. There were 12 unique FAERS cases coded with an outcome of death. Analysis of these reports did not find any report of death causally linked to use of IV phenylephrine; nor were there any unique patterns of adverse events across age groups, gender, country of reporter, or location of use. The published literature search of adverse events associated with phenylephrine retrieved one article describing stress cardiomyopathy in an obstetric patient undergoing spinal anesthesia as well as a number of articles reporting maternal bradycardia (labeled) in obstetric patients. The majority of articles retrieved from a review of the published medical literature focused on the efficacy of phenylephrine.
Our review of all unlabeled adverse events did not find any events that were sufficiently compelling to suggest a new safety signal or to require any addition to the proposed phenylephrine labeling. DPV will continue routine monitoring of all adverse events reported in association with phenylephrine HCl 1% injection.

**Outstanding or Unresolved Issues**
I concur with the review team that the safety profile of phenylephrine has been adequately characterized by the extensive history of clinical use, the published literature, and evaluation of the FDA’s Adverse Event Report System.

**10. Advisory Committee Meeting**
An advisory committee meeting was not convened for this application, as there were no issues in this application that required presentation or discussion at an advisory committee meeting.

**10. Pediatrics**
The Applicant requested a waiver of the studies required under the Pediatric Research Equity Act of 2007 (PREA) The Division concurred with the Applicant with respect to patients less than 12 years of age, but considered the studies for patients older than 12 years as possible and desirable, in that dosing information in this age group would be relevant and useful to obtain.

At the Pediatric Review Committee (PeRC) meeting of March 5, 2014, the committee reviewed the Applicant’s proposal and the division’s position, and concurred with the division that the study in the older age group would be useful. It was also decided that this study could be deferred.

These conclusions were conveyed to the Applicant and a timeline for the submission of the final report submission was agreed upon.

**11. Other Relevant Regulatory Issues**
Consultations were obtained from the Office of Professional Drug Promotion, the Division of Medication Error Prevention and Analysis, and the Study Endpoints and Labeling Development team. Their recommendations were reviewed and incorporated in the appropriate places in the label.

Consultation was also obtained from the Division of Bone, Reproductive, and Urologic Products with regard to the safety of the use of phenylephrine during labor and delivery.

**OSI / Division of Good Clinical Practice Compliance (DGCPC) Audits**
There were no clinical trials conducted by the Applicant, therefore, there was no need for audits to be conducted by the DGCPC.

**Financial Disclosure**
The Applicant did not conduct any clinical trials in support of this application. Therefore, the Applicant did not need to make any statement regarding financial disclosures for investigators.
Outstanding or Unresolved Issues
There are no other unresolved relevant regulatory issues.

12. Labeling
In addition to the review disciplines mentioned above, representatives from the Division of Medication Error Prevention and Analysis, the Office of Prescription Drug Promotion, and the Pediatric and Maternal Health Staff were also consulted and their recommendations were incorporated during the discussion of the label.

Since the clinical entity of hypotension can be due to a variety of etiologies, and the decision as to when it should be treated is dependent on the clinical circumstances, the indication statement will be modified to reflect that phenylephrine is indicated for treatment of clinically hypotension resulting primarily from vasodilation in the setting of anesthesia.

13. Decision/Action/Risk Benefit Assessment

Regulatory Action
1. Treatment of Hypotension: Complete Response
Although the Applicant submitted sufficient information to support approval of phenylephrine for the indication of “treatment of hypotension during anesthesia,” the withhold recommendation entered into the EES precludes approval of this application at this time.

Risk:Benefit Assessment
I concur with the review team that the Applicant has submitted substantial evidence to support the effectiveness and safety of phenylephrine for the treatment of hypotension that is primarily associated with vasodilation. Even though phenylephrine has been associated with the risk of hypertension and reflex bradycardia, an episode of perioperative hypotension is associated with increased morbidity and mortality, whereupon the use of phenylephrine in this clinical situation results in a favorable risk:benefit assessment.
Recommendation for Postmarketing Risk Management Activities
None.

Recommendation for other Postmarketing Study Requirements
These requirements have been discussed with the Applicant during the course of the review of the application, but they will not be officially communicated in the CR letter because the application is not being approved at this time.

Clinical (as part of the PREA requirements)
A clinical study in patients between the ages of 12 and 16 years of age, to evaluate the dose effect of phenylephrine administration on blood pressure in patients undergoing general anesthesia or neuroaxial anesthesia.

Non-clinical
1. A fertility and early embryonic development toxicology study in the rat model for phenylephrine hydrochloride.
2. An embryo-fetal developmental toxicology study using the rat model for phenylephrine hydrochloride.
3. An embryo-fetal developmental toxicology study using the rabbit model for phenylephrine hydrochloride.
4. A peri- and post-natal developmental toxicology study in the rat model for phenylephrine hydrochloride.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RIGOBERTO A ROCA
04/28/2014